August 28, 2026 09:58 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Kanpur plane crash: Training aircraft crashes near Ganges, two pilots killed | Big IT boost for Bengal: LTM opens global delivery & AI centre in Kolkata's New Town | 21-year-old Delhi model found stabbed at Delhi home, gym trainer accused of killing her | ‘Who is stopping her from wearing what she wants?’: Kangana Ranaut hits back at Kriti Sanon over Raksha Bandhan ad | 300 Indians missing in Nepal flash floods, 160 dead: Foreign Minister reveals grim toll | Supreme Court directs Tarun Tejpal to surrender within two weeks | Supreme Court notice to 20 rebel TMC MPs in disqualification plea | ‘Reservation for poor, not caste’: Stir at Delhi’s Jantar Mantar | Dalit woman 'gangrape-murder' shocker in Karnataka: 4 arrested after body found in well | India dismisses Pakistan's 'frustration' over US envoy's J&K remark
UNI

India records 48,900 new COVID-19 cases, death toll touches 31358

| @indiablooms | Jul 25, 2020, at 03:23 pm

New Delhi: India registered 48,916 new COVID-19 cases in the past 24 hours while the death toll due to the highly infectious disease now stands at 31358, as per Ministry of Health data released on Saturday.

Meanwhile, the number of COVID-19 cases in the country now stands at 1,336,861.

There are 456071 active cases in the country at present.

So far, 849431 people have recovered from the disease.

COVAXIN human trial begins:

The clinical trial of the country's first indigenously-developed vaccine against Novel Coronavirus - COVAXIN began at AIIMS here on Friday, with the first dose of the injection given to a man, nearing his 30s.

According to Dr Sanjay Rai, Professor at the Centre for Community Medicine at AIIMS and principal investigator of the study, ''We had called two people for the human trial, but only one of them turned up.''

Prof Rai said after administering the medicine, the person was put under observation for two hours. No side effect of the vaccine was noted, he added.

His health will be monitored for the coming two weeks, said the Medico, adding that other volunteers will be administered the vaccine on Saturday.

All the volunteers chosen for the two-phase study are healthy people, with no underlying conditions, such as Diabetes or Blood Pressure, Prof Rai said, adding that the study will check the number of antibodies produced after administering of the vaccine.

Total 1,125 people will be administered the vaccine, being formulated jointly by Bharat Biotech, the Indian Council of Medical Research (ICMR) and the National Institute of Virology, Pune.  

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.